Mivacurium chloride

Bis [3 - [( 1R) -6,7- dimethoxy -2-methyl -1-[ (3,4,5- trimethoxyphenyl) methyl] -3,4- dihydro-1H -isoquinoline -2- ium -yl] propyl] (E) -oct -4- enedioat (IUPAC)

M03AC10

Muscle relaxant

Template: Infobox chemical / molecular formula search available

Mivacurium (trade name Mivacron (EU, CH), Manufacturer: Glaxo Smith Kline ) is a drug which was introduced as a short-acting muscle relaxant nichtdepolarisierendes from the group of benzylisoquinoline 1997. There are three isomers ( composition of approximately 60% trans, trans, 35% cis-trans, 5% cis -cis ), the cis, cis- form has only about a tenth of the effect.

Following administration of a standard intubating the stop time is about three to five minutes, the duration of action 15 to 25 minutes. It can lead to the release of histamine, causing redness of the skin, tachycardia, hypotension, bronchospasm and urticaria can be triggered. The application is in infants under two months, people with contraindicated Pseudocholinesterasemangel and (relatively) in asthmatics.

The degradation takes place (as with succinylcholine ) in plasma by pseudocholinesterase. In innate or acquired deficiency of this enzyme, the duration of action can be extended (up to several hours). Mivacurium is converted into three metabolites ( quaternary amino alcohol, quaternary monoester, dicarboxylic acid ).